Recursion gets FDA approval to begin phase 1 trials of AI-discovered cancer treatment

AI drug pioneer Recursion Pharmaceuticals said Wednesday that one of its experimental treatments hit a key milestone. Recursion was able to use its artificial intelligence-enabled drug discovery platform to identify an area of biology to target for the treatment of solid tumors and lymphoma, match it with a drug candidate and move all the way to gaining regulatory approval to begin studies in less than 18 months. "We think that's a really exciting proof point, not only for us as a company, but I think for t ...